---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-010278"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:12:05.096515+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tenax Therapeutics closes $100M private placement to fund Phase 3 levosimendan program

## Summary
- Gross proceeds of ~$100M from oversubscribed private placement led by BVF Partners.
- Issued 1,450,661 common shares at $3.00, plus pre-funded warrants for 31,882,671 shares and warrants for 16,666,666 shares.
- Funds will complete ongoing LEVEL Phase 3 study and initiate a second Phase 3 study in 2025, shortening NDA timeline.
- Oral levosimendan (TNX-103) targets PH-HFpEF, a disease with no approved therapies; earlier HELP study showed 29-meter 6MWD improvement.
- Leerink Partners, Guggenheim Securities, and William Blair acted as placement agents; ROTH Capital advised Tenax.

## SEC filing metadata
- accession: 0001654954-24-010278
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000165495424010278/0001654954-24-010278-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000165495424010278/tenx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-010278
- JSON: https://secwatch.observer/filing/0001654954-24-010278.json
- Plain text: https://secwatch.observer/filing/0001654954-24-010278.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.